食管癌患者放化疗后中医证型的相关影响因素

目的 观察消风散加减方联合依巴斯汀治疗风热型荨麻疹的临床疗效。 方法 将63例风热型荨麻疹患者按随机数字表法随机分为治疗组（n=32）和对照组（n=31），对照组患者口服依巴斯汀，治疗组口服依巴斯汀和消风散加减方，疗程2周。治疗前、治疗7 d末、治疗14 d末，分别观察两组患者荨麻疹活动度评分（urticaria activity score，UAS）和皮肤病生活质量指数（the dermatology life quality index，DLQI），治疗7 d和14 d末，分别观察两组临床疗效。 结果 治疗前和治疗7 d末，两组UAS及DLQI比较，差异均无统计学意义（P>0.05）；治疗14 d末，两组UAS和DLQI比较，差异具有统计学意义（P<0.05）。治疗7 d末和14 d末，两组UAS和DLQI均较前一时点显著降低（P<0.05）。治疗14 d末，两组临床疗效比较，差异具有统计学意义（P<0.05），治疗组临床疗效优于对照组。两组荨麻疹痊愈时间以及复发率比较，差异均无统计学意义（P>0.05）。 结论 消风散加减方联合依巴斯汀治疗急性荨麻疹疗效确切，其长期疗效优于单用依巴斯汀。

Influencing Factors for Traditional Chinese Medicine Syndrome Types in Patients with Esophageal Cancer after Chemoradiotherapy

Objective To investigate the influencing factors for traditional Chinese medicine (TCM) syndrome types in patients with esophageal cancer before and after chemoradiotherapy. Methods The TCM syndrome differentiation was performed in 120 patients with esophageal cancer before and after chemoradiotherapy. The influencing factors for TCM syndromes were evaluated using multivariate logistic regression analysis. Results In all the patients with esophageal cancer, the incidence rates of syndrome of intermingled phlegm and qi and syndrome of blood stasis and phlegm stagnation were significantly reduced after chemoradiotherapy (34.2% vs 10.0%, P<0.05; 37.5% vs 30.0%, P<0.05), while the incidence rates of syndrome of yin deficiency and heat toxicity and syndrome of qi deficiency causing weak yang were significantly elevated after chemoradiotherapy (25.8% vs 40.0%, P<0.05; 2.5% vs 20.0%, P<0.05). Before chemoradiotherapy, the TCM syndrome types in patients were significantly correlated with Karnofsky Performance Status (KPS) score, marrow suppression grade, and primary site (P<0.05). After chemoradiotherapy, the TCM syndrome types in patients were significantly correlated with KPS score and primary site (P<0.05). Conclusion Patients with esophageal cancer showed significant changes in TCM syndrome types after chemoradiotherapy. The TCM syndrome types are correlated with KPS score, marrow suppression grade, and primary site.